Weekly Funding Opportunities

[Med Research]

BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-20-006.html>
A central goal of the BRAIN Initiative is to develop new and improved technologies suitable for recording from as well as controlling specified cell types and circuits to modulate and understand function in the central nervous system. In order to accomplish these goals, further information is needed to understand the function of current technologies used for recording or stimulating the nervous system.
This RFA accepts grant applications in two related but distinct areas. The first is to systematically characterize, model, and validate the membrane, cellular, circuit, and adaptive-biological responses of neuronal and non-neuronal cells to various types of stimulation technologies. The second is to understand the biological and bioinformatic content of signals recorded from neuronal and non-neuronal cells and circuits. Development of new technologies, therapies and disease models is outside the scope of this FOA. Activities related to enabling the simultaneous use of multiple recording or stimulation technologies are allowed.
Due March 24, 2020; June 2, 2020; October 1, 2020; February 2, 2021; June 1, 2021; October 1, 2021; February 1, 2022; June 1, 2022; and October 3, 2022. Med-RA deadline to receive draft documents for March 2020 deadline: March 11.

Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21 / R01 - Clinical Trial Not Allowed)
R21<https://grants.nih.gov/grants/guide/pa-files/PAR-20-081.html>
R01<https://grants.nih.gov/grants/guide/pa-files/par-20-088.html>
The purpose of these initiatives is to support multidisciplinary research to understand the underlying etiologic factors and mechanisms that contribute to population-level disparities in chronic liver diseases and liver cancer in the U.S.
Due April 1, 2020; April 1, 2021; and April 1, 2022. Med-RA deadline to receive draft documents for April 2020 deadline: March 19.

Alzheimer's Drug Discovery Foundation: Prevention Beyond the Pipeline<https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline>
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Specifically, the Prevention Beyond the Pipeline RFP supports:

  1.  Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA): Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods or supplements. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script.
  2.  Comparative Effectiveness Research: For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond the treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect from dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition. Methods may include randomized trials or epidemiology.
  3.  Studies of Cognitive Decline and Cognitive Reserve: Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding programs to prevent and treat these conditions, including cognitive aging, menopause-related cognitive symptoms, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include epidemiology or clinical trials. For clinical trial proposals, please see below detailed instructions and priorities under “Funding Priorities for Clinical Trial Proposals” and “Evaluation of Clinical Trial Proposals”.
Current target areas of interest include epigenetics, inflammation, mitochondria and metabolic function, neuroprotection, proteostasis, synaptic activity and neurotransmitters, vascular function, other aging targets (e.g., senescent cells), and other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to age-related cognitive decline or dementia risk. Average duration: One year for epidemiological analyses. Varies (multi-year) for clinical trials. Average Award: $50,000-$100,000 for epidemiological analyses based on scope of research. Up to $3 million for clinical trials based on stage and scope of research.
Letter of intent due April 10, July 10, and October 9, 2020. Med-RA deadline to receive draft documents for April 2020 deadline: March 30.

Alzheimer's Drug Discovery Foundation: Drug Development Program<https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-program>
The goal of this RFP is to develop therapeutics for Alzheimer's disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years.
Specifically, the Drug Development RFP supports:

  *   Preclinical pharmacokinetics, pharmacodynamics, target engagement, and preliminary rodent tolerability
  *   In vivo efficacy or proof-of-concept studies
Applications that focus on basic science, target identification, target validation, assay development, and high-throughput screening are not a priority for this RFP and will be withdrawn.
The ADDF is interested in small molecules and biologics (e.g. antibodies, peptides, gene therapies). Both novel programs and repurposing/repositioning of approved or clinically safe therapies from other disease indications are appropriate for this RFP. Current target areas of interest include epigenetics, inflammation, mitochondria and metabolic function, neuroprotection, proteostasis, synaptic activity and neurotransmitters, vascular function, other aging targets (e.g., senescent cells), and other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to the disease process
This RFP does not support anti-amyloid approaches (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitors.
Average Duration: One year with potential for follow-on funding. Multi-year proposals can be considered. Average Award: $150,000-$600,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Letter of intent due April 10, 2020; July 10, 2020; and October 9, 2020. Med-RA deadline to receive draft documents for April 2020 deadline: March 30.

Mendelian Genomics Research Centers (U01 - Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/rfa-hg-20-007.html>
The purpose of this Funding Opportunity is to establish a consortium aimed at significantly increasing the proportion of Mendelian conditions with an identified genetic cause. A key objective of the Mendelian Genomics Research Centers is to develop and apply approaches to discover causal genes underlying Mendelian conditions for which a candidate gene was not identified using whole exome sequencing alone.
Due April 15, 2020. Med-RA deadline to receive draft documents: April 2.

Research Answers to National Cancer Institute’s (NCI) Provocative Questions (R21 / R01 Clinical Trial Optional)
R21<https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-20-005.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/rfa-ca-20-004.html>
The purpose of these Funding Opportunity Announcements (FOAs) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI’s priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention.
Some of these “Provocative Questions” (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances.
The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to these FOAs must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.
PQs:

  *   What are the underlying causes of the unexplained rising incidence in early-onset cancers?
  *   How does intermittent fasting affect cancer incidence, treatment response, or outcome?
  *   How do selective pressures affect cell competition and cooperation during cancer initiation and development?
  *   What mechanisms explain sex differences in cancer incidence, lesion location, or response to therapy?
  *   What strategies can block or reverse the emergence of new cell lineage states induced by cancer treatments?
  *   How can cancer cachexia be reversed?
  *   What methods can be developed to integrate patient-generated health data into electronic health records?
  *   What strategies improve and sustain coordination of comprehensive healthcare for underserved cancer patients with comorbidities?
  *   What methods can be developed to effectively study small or rare populations relevant to cancer research?
Due April 30, 2020 and November 17, 2020. Med-RA deadline to receive draft documents for April 2020 deadline: April 20.

National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-077.html>
With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 11.

Development of Research Education Resources for Geriatrics-Related Translational and Clinical Scientists (R25 Independent Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-095.html>
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on the following:
Curriculum or Methods Development: This FOA is intended to support the development of a multi-disciplinary clinical and translational geriatrics-related research curriculum that will be used in future training programs for clinician-scientists. Such resource development will fill a need not currently addressed by existing NIH- and NIA-supported programs. Proposed resources should improve geriatrics research education through innovative programs, novel instructional approaches, computer-based tools, problem-based learning, and other effective strategies. Specific research education topics may include, but are not limited to, the following:

  *   Scientific approaches to prevention and management of multimorbidity
  *   Clinical investigation and clinical trials of geroscience-related interventions
  *   Development and incorporation of functional outcomes into clinical studies
  *   Research approaches toward treatment of geriatric conditions and disease management within a geriatric framework
  *   Recruitment of diverse populations of older adults into clinical research studies
  *   Research approaches to geriatric health disparities
Courses for Skills Development: In addition to development of a curriculum, this FOA can also support testing and refinement of the curriculum through courses. Such implementation, if proposed, is expected in the latter years of the R25 award.
Research Experiences: If warranted, this FOA can also support hands-on research experiences for the purposes of testing and refining the curriculum in the latter years of the R25 award.
Standard dates apply. Expires January 26, 2023. Med-RA deadline to receive draft documents for May 25, 2020 standard date: May 11.

Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-093.html>
This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research that demonstrates an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms.
Due May 27, 2020; May 26, 2021; and May 24, 2022. Med-RA deadline to receive draft documents for May 2020 deadline: May 13.

NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAR-20-072.html>
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of healthy immune system development and function across the lifespan; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for proposed research.
Due June 11, 2020; January 11, 2021; June 11, 2021; January 11, 2022; and June 10, 2022. Med-RA deadline to receive draft documents for June 2020 deadline: May 13.

Glial Plasticity in the Aging Brain (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-010.html>
Recent reports highlight the enormous spatial and temporal diversity of glia, even within the same glial cell type. This within-glial-cell-type heterogeneity evolves during aging, suggesting that subtypes of glia with distinct physiological roles could emerge to influence brain aging processes. The goal of this Funding Opportunity Announcement is to support research addressing critical knowledge gaps in our understanding of how these glial subpopulations could contribute to vulnerability and resilience to brain aging.
Due June 17, 2020. Med-RA deadline to receive draft documents: June 4.

Mechanisms of Rejuvenation and Age-Acceleration in Heterochronic Blood Exchange (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-002.html>
This FOA will support research on aspects of rejuvenation and accelerated aging observed specifically in heterochronic blood exchange (HBE) experiments. The objectives are to identify the multiple factors involved, the multiple cell types involved, and the mechanisms underlying rejuvenation or accelerated aging that are observed in the transfer of phenotypes between young and old laboratory animals. It is also anticipated that molecular signatures of rejuvenation or accelerated aging will be obtained from research supported under this FOA.
Due June 17, 2020. Med-RA deadline to receive draft documents: June 4.

NSF: Developmental Sciences (DS)<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=8671&WT.mc_id=USNSF_39&WT.mc_ev=click>
DS supports basic research that increases our understanding of cognitive, linguistic, social, cultural, and biological processes related to human development across the lifespan. Research supported by this program will add to our knowledge of the underlying developmental processes that support social, cognitive, and behavioral functioning, thereby illuminating ways for individuals to live productive lives as members of society. DS supports research that addresses developmental processes within the domains of cognitive, social, emotional, and motor development across the lifespan by working with any appropriate populations for the topics of interest including infants, children, adolescents, adults, and non-human animals. The program also supports research investigating factors that affect developmental change including family, peers, school, community, culture, media, physical, genetic, and epigenetic influences. Additional priorities include research that: incorporates multidisciplinary, multi-method, microgenetic, and longitudinal approaches; develops new methods, models, and theories for studying development; includes participants from a range of ethnicities, socioeconomic backgrounds, and cultures; and integrates different processes (e.g., memory, emotion, perception, cognition), levels of analysis (e.g., behavioral, social, neural), and time scales. The budgets and durations of supported projects vary widely and are greatly influenced by the nature of the project. Investigators should focus on innovative, potentially transformative research plans and then develop a budget to support those activities, rather than starting with a budget number and working up to that value. While there are no specific rules about budget limitations, a typical project funded through the DS program is approximately 3 years in duration with a total cost budget, including both direct and indirect costs, between $100,000 and $200,000 per year.
Due July 15, 2020. January 15 and July 15 annually thereafter. Med-RA deadline to receive draft documents for July 2020 deadline: July 1.

NSF: Social Psychology<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5712&WT.mc_id=USNSF_39&WT.mc_ev=click>
The Social Psychology Program at NSF supports research and research infrastructure to advance basic knowledge in social psychology. Projects funded by the Social Psychology Program support the NSF mission to promote the progress of science; to advance the national health, prosperity, and welfare; and to secure the national defense. Proposed research should carry strong potential for creating transformative advances in the basic understanding of human social behavior.  Among the many research topics supported are: social cognition, attitudes, social and cultural influence, stereotypes, motivation, decision making, group dynamics, aggression, close relationships, social and affective neuroscience, social psychophysiology, emotions, prosocial behavior, health-related behavior, and personality and individual differences. Proposals that develop new theories or methods for understanding social behavior are highly encouraged.  Research samples should represent substantial ranges of ethnicities, socioeconomic backgrounds, cultures, and other dimensions of human populations.
Proposals involving non-human animals are considered only if the research offers clear and direct contributions to understanding human social behavior. The program does not fund research that seeks to improve clinical practice as its primary outcome, nor does it consider proposals with disease-related goals, including work on the etiology, diagnosis or treatment of physical or mental disease, abnormality, or malfunction in human beings or animals.
Due July 15, 2020. January 15 and July 15 annually thereafter. Med-RA deadline to receive draft documents for July 2020 deadline: July 1.

NSF: Biological Anthropology<https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5407&WT.mc_id=USNSF_39&WT.mc_ev=click>
The Biological Anthropology Program supports basic research in areas related to human evolution and contemporary human biological variation. Research areas supported by the program include, but are not limited to, human genetic variation, human and nonhuman primate ecology and adaptability, human osteology and bone biology, human and nonhuman primate paleontology, functional anatomy, and primate socioecology. Grants supported in these areas are united by an underlying evolutionary framework, and often by a consideration of adaptation as a central theoretical theme. Proposals may also have a biocultural or bioarchaeological orientation. The program frequently serves as a bridge within NSF between the social and behavioral sciences and the natural and physical sciences, and proposals commonly are jointly reviewed and funded with other programs.
Due July 20, 2020. January 20 and July 20 annually thereafter. Med-RA deadline to receive draft documents for July 2020 deadline: July 7.


To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.


-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200130/e2a4f0ce/attachment.html>